ADVENTRX (NYSE: ANX), a San Diego-based biopharmaceutical company, has made some strides in the development of a product candidate designed to treat genetic hematoma disorders, specifically sickle cell anemia (SCA), an orphan drug market with implications for millions of people.
EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
ADVENTRX Pharmaceuticals, Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates principally for the treatment of cancer, recently provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.
Day 2 at the OneMed Forum highlighted a series of exciting presentations & networking opportunities.
The New York Society of Security Analysts, a leading forum for the investment community, recently announced the presenter list for its 14th Annual Biotech and Specialty Pharma Conference.
OneMedPlace announced today that its “OneMedForum 2011” business development and finance conference for emerging healthcare and life science companies will be held January 11-13, 2011, in San Francisco at the Sir Francis Drake Hotel.
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
Copyright © 2024 | WordPress Theme by MH Themes